Success Stories: We Administered a Post-Doctoral Scholar from India in the Field of Bioinformatics in Securing NIW Approval within 6 Days

Client’s Testimonial:

“I am writing to express my heartfelt gratitude for your outstanding efforts in successfully securing the approval of my I-140 NIW application. I am absolutely thrilled to receive the news of its approval and couldn’t have achieved this without your expert guidance and support throughout the entire process. Thanks!!”

On October 16^th, 2023, we received another EB-2 NIW (National Interest Waiver) approval for a Post-Doctoral Scholar in the field of Bioinformatics (Approval Notice).

General Field: Bioinformatics

Position at the Time of Case Filing: Post-Doctoral Scholar

Country of Origin: India

State of Residence at the Time of Filing: Pennsylvania

Approval Notice Date: October 16^th, 2023

Processing Time: 6 days (Premium Processing Requested)

Case Summary:

Our client seeking advancement in the bioinformatics field approached our law firm to file an I140 NIW (National Interest Waiver) petition on his behalf. He had a Ph.D. in bioinformatics and substantial research expertise. When we looked further into his degrees and certificates and reviewed all of his qualifications, we were certain that we could help him succeed at the NIW case and countersigned the retainer agreement.

To establish that he is an integral researcher in his field of expertise, we incorporated crucial attributes into his NIW (National Interest Waiver) petition packet.

Firstly, we noted that his work has been cited 403 times by dependent and independent researchers, affirming that not only has he effectively finished and published the findings of his field research, but his work has also influenced his peers in at least 63 different nations, indicating that they are well-known and dependable in the bioinformatics community.
We also detailed his research, which resulted in 12 peer-reviewed journal articles (5 of them first-authored) and 1 book chapter, published in four highly regarded peer-reviewed journals.
In addition, we discussed how our client has completed at least 16 peer reviews to date.

Furthermore, our client’s research on the identification of genes linked to climate change adaptability has significant merit and national significance because it

is relevant to treating drug-resistant infections and reducing the morbidity and mortality of infectious diseases;
addresses some of our nation’s and the world’s most pressing issues, including how to effectively evaluate R-genes in plant genomes, how to improve resilience to withstand severe climate change, and how to enhance the adaptive capacity of major endangered species.

Due to its clear national importance, his research has also been supported with funding from:

The National Institute of Food and Agriculture;
The Institute for Systems Genomics;
The Pennsylvania Center for Poultry and Livestock Excellence; etc.

Therefore, this funding support is proof that his groundbreaking study on the redwood genome is critical for furthering the scientific knowledge of plant genomics and accelerating the process of forest regeneration.

Overall, he delivers contributions of such value that, they would benefit the United States even though other qualified U.S. workers are available, especially considering our client’s track record of successful research in an area that significantly advances U.S. interests. Successfully, he was approved for a National Interest Waiver (NIW). As a result, we express our gratitude to him for selecting the North America Immigration Law Group to handle his case and send him our best wishes for future success in his chosen endeavor.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.